Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | ODC1 | P11926 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29404075 | 1.00 | ALDH1A1 (0.54) | ALDH1A1CYP3A4HPGDTDP1PPARG | |
| Prococene Ii SCHEMBL119925 | 0.86 | ODC1 (0.54) | ALDH1A1CYP3A4HPGDTDP1ODC1 | |
| SCHEMBL8881498 | 0.81 | ODC1 (0.49) | ODC1HIF1AEPAS1 | |
| SCHEMBL11012720 | 0.79 | TLR3 (0.48) | ODC1HIF1AEPAS1 | |
| Encecalin SCHEMBL4310132 | 0.79 | ALDH1A1 (0.68) | ALDH1A1CYP3A4HPGDTDP1PTPN1 | |
| SCHEMBL10510924 | 0.78 | TLR3 (0.53) | HIF1AEPAS1 | |
| Prococene Ii SCHEMBL1070896 | 0.78 | TLR3 (0.53) | HIF1AEPAS1 | |
| SCHEMBL119216 | 0.78 | TLR3 (0.53) | HIF1AEPAS1 | |
| SCHEMBL15477922 | 0.77 | ODC1 (0.49) | ODC1HIF1AEPAS1 | |
| SCHEMBL10508119 | 0.77 | ODC1 (0.46) | ODC1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 383 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7153490-B2 | Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumors | LIPOTEC, SA (ES) | 2006-12-26 | — | — | US | claimed |
| EP-1325739-B1 | LIPOSOMES ENCAPSULATING ANTICANCER DRUGS AND THE USE THEREOF IN THE TREATMENT OF MALIGNANT TUMORS | LIPOTEC SA (ES) | 2006-03-01 | — | — | EP | claimed |
| US-20050100590-A1 | Liposomes encapsulating anticancer drugs and use thereof in the treatment of malignant tumours | GP PHARM S.A. (ES) | 2005-05-12 | — | — | US | claimed |
| EP-1325739-A1 | LIPOSOMES ENCAPSULATING ANTICANCER DRUGS AND THE USE THEREOF IN THE TREATMENT OF MALIGNANT TUMORS | Lipotec, S.A. (ES) | 2003-07-09 | — | — | EP | claimed |
| EP-1267813-A2 | USE OF PROTEASE INHIBITORS IN COSMETICS AND PHARMACY | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-01-02 | — | — | EP | claimed |
| WO-2001074320-A2 | USE OF PROTEASE INHIBITORS IN COSMETICS AND PHARMACY | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-10-11 | — | — | WO | claimed |
| EP-4110277-B1 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS | SYMRISE AG (DE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3045161-B1 | Use of active mixtures of 1,2-hexanediol and 1,2-octanediol in cosmetic, pharmaceutical or dermatological emulsions | SYMRISE AG (DE) | 2026-03-25 | — | — | EP | disclosed |
| EP-4706780-A2 | COMPOSITIONS COMPRISING UV-FILTERS AND ONE OR MORE (BIO)-ALKANEDIOLS | Symrise AG (DE) | 2026-03-11 | — | — | EP | disclosed |
| EP-4110276-B1 | COMPOSITIONS COMPRISING ALKANEDIOLS | SYMRISE AG (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4616840-A2 | COMPOSITIONS COMPRISING (BIO)-ALKANEDIOLS WITH ANTIMICROBIALS FOR PRODUCT PROTECTION | Symrise AG (DE) | 2025-09-17 | — | — | EP | disclosed |
| US-12403076-B2 | Compositions comprising odorless 1,2-pentanediol | SYMRISE AG (DE) | 2025-09-02 | — | — | US | disclosed |
| EP-4603149-A2 | A PRESERVATIVE MIXTURE | Symrise AG (DE) | 2025-08-20 | — | — | EP | disclosed |
| WO-2006045760-A1 | USE OF GLYCOSYLATED FLAVANONES FOR THE BROWNING OF SKIN OR HAIR | SYMRISE GMBH & CO. KG (DE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006015726-A1 | PREBIOTIC INTIMATE PERSONAL HYGIENE PRODUCT | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2006-02-16 | — | — | WO | disclosed |
| WO-2005092279-A1 | SUBSTANCES WITH A PROBIOTIC ACTION USED IN DEODORANTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-10-06 | — | — | WO | disclosed |
| WO-2005037239-A2 | USE OF A COMPOUND FROM THE GROUP OF HETERODIAZOLES OR A SALT OF SAID COMPOUND, COSMETIC OR THERAPEUTIC FORMULATION CONTAINING SAID COMPOUND OR SALT, SAID COMPOUND OR SALT AS A THERAPEUTIC AGENT, AND SAID SALT | SYMRISE GMBH & CO. KG (DE) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005011716-A1 | PREBIOTICALLY ACTIVE PLANT EXTRACTS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2005-02-10 | — | — | WO | disclosed |
| EP-1267813-A2 | USE OF PROTEASE INHIBITORS IN COSMETICS AND PHARMACY | Henkel Kommanditgesellschaft auf Aktien (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001074320-A2 | USE OF PROTEASE INHIBITORS IN COSMETICS AND PHARMACY | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 2001-10-11 | — | — | WO | disclosed |